Drug Makers Designing Better Ingredients For Hep C Drug Cocktails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As the field of hepatitis C therapy opens up with the specifically targeted antiviral therapies for HCV, the combination of drugs used to treat the chronic disease will be in flux. While the likely key ingredients are pretty well known, and for the immediate future will retain an interferon/ribavirin backbone, a few smaller companies are starting to demonstrate what they can add to the mix
You may also be interested in...
Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor
GlobeImmune Gets A Shot In The Arm Thanks To Celgene Cancer Collaboration
Hepatitis C vaccine success validated technology and paved way for the deal.
INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark